Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients
Primary Purpose
Kidney Transplantation
Status
Unknown status
Phase
Locations
Italy
Study Type
Observational
Intervention
Sponsored by

About this trial
This is an observational trial for Kidney Transplantation focused on measuring kidney, transplant, Mycophenolic acid, Inosine monophosphate dehydrogenase
Eligibility Criteria
Inclusion Criteria:
- Renal transplant recipients
- Age range: 18-70
- Patients taking MMF
- Able to understand and sign an informed consent
Exclusion Criteria:
- Active myelodepression
- Systemic infections or other that may affect MMF absorption
- Pregnancy/breastfeeding
- (History of) cancer
- Drug abuse, psychiatric conditions
- Already enrolled in other clinical trials or participation ended less than one month earlier
- Known sensitivity to polysorbate 80 or MMF
Sites / Locations
- IRCCS Fondazione Policlinico San Matteo
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Arm Label
1
2
3
Arm Description
MMF+cyclosporine
MMF+tacrolimus
MMF+sirolimus
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00780429
First Posted
October 24, 2008
Last Updated
October 24, 2008
Sponsor
IRCCS Policlinico S. Matteo
1. Study Identification
Unique Protocol Identification Number
NCT00780429
Brief Title
Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients
Official Title
Evaluation of Pharmacokinetic and Pharmacodynamic Parameters in Renal Transplant Patients Receiving Mycophenolic Acid and Stable for at Least 3 Months
Study Type
Observational
2. Study Status
Record Verification Date
October 2008
Overall Recruitment Status
Unknown status
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
IRCCS Policlinico S. Matteo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Study of the pharmacokinetic and pharmacodynamic variability of mycophenolate mofetil in renal transplant patients already on long-term MMF treatment (at least 6 months post-transplant; at least 3 months in therapy).
Study hypothesis: to investigate whether long-term MMF therapy alters IMPDH biological activity and if there are any correlations with the risk of AR.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Transplantation
Keywords
kidney, transplant, Mycophenolic acid, Inosine monophosphate dehydrogenase
7. Study Design
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Description
MMF+cyclosporine
Arm Title
2
Arm Description
MMF+tacrolimus
Arm Title
3
Arm Description
MMF+sirolimus
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Renal transplant recipients
Age range: 18-70
Patients taking MMF
Able to understand and sign an informed consent
Exclusion Criteria:
Active myelodepression
Systemic infections or other that may affect MMF absorption
Pregnancy/breastfeeding
(History of) cancer
Drug abuse, psychiatric conditions
Already enrolled in other clinical trials or participation ended less than one month earlier
Known sensitivity to polysorbate 80 or MMF
Study Population Description
Male and female renal transplant patients
Sampling Method
Non-Probability Sample
Facility Information:
Facility Name
IRCCS Fondazione Policlinico San Matteo
City
Pavia
ZIP/Postal Code
27100
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients
We'll reach out to this number within 24 hrs